Genetic polymorphisms of CYP2A6 affect the in-vivo pharmacokinetics of pilocarpine

Pharmacogenetics and Genomics

Volumn 18, Issue 9, 2008, Pages 761-772

  Endo, Takuro ^a   Nakajima, Miki ^b   Fukami, Tatsuki ^b   Hara, Yoshiki ^a   Hasunuma, Tomoko ^c   Yokoi, Tsuyoshi ^b   Momose, Yasunori ^a  

^a KISSEI PHARMACEUTICAL CO LTD   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c KITASATO INSTITUTE   (Japan)

Author keywords

CYP2A6; Genetic polymorphisms; Metabolites; Pharmacokinetics; Pilocarpine

Indexed keywords

3 HYDROXYPILOCARPINE; CYTOCHROME P450 2A6; DRUG METABOLITE; PILOCARPIC ACID; PILOCARPINE; UNCLASSIFIED DRUG; 3-HYDROXYPILOCARPINE; COUMARIN 7 HYDROXYLASE; COUMARIN 7-HYDROXYLASE; DRUG DERIVATIVE; MUSCARINIC AGENT; UNSPECIFIC MONOOXYGENASE;

ADULT; AGED; ALLELE; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CYP2A6 10 GENE; CYP2A6 4A GENE; CYP2A6 7 GENE; CYP2A6 9 GENE; CYP2A6 GENE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; FLUSHING; GENE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN EXPERIMENT; JAPANESE; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SWEATING; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY EXCRETION; GENETICS; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; AGED; ARYL HYDROCARBON HYDROXYLASES; HUMANS; MALE; MIDDLE AGED; MUSCARINIC AGONISTS; PILOCARPINE; POLYMORPHISM, GENETIC;

EID: 53049101063     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e328303c034     Document Type: Article

References (30)

1. Hoyng PF, Van Beek LM. Pharmacological therapy for glaucoma: a review. Drugs 2000; 59:411-434.
2. Rhodus NL, Schuh MJ. Effects of pilocarpine on salivary flow in patients with Sjögren's syndrome. Oral Surg Oral Med Oral Pathol 1991; 72:545-549.
3. Johnson JT, Ferretti GA, Nethery WJ, Valdez IH, Fox PC, Ng D, et al. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N Engl J Med 1993; 329:390-395.
4. Vivino FB, Al-Hashimi I, Khan Z, LeVeque FG, Salisbury PL III, Tran-Johnson TK, et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren's syndrome. Arch Intern Med 1999; 159:174-181.
5. Nyárády Z, Németh Á, Bán Á, Mukics A, Nyá rády J, Ember I, et al. A randomized study to assess the effectiveness of orally administered pilocarpine during and after radiotherapy of head and neck cancer. Anticancer Res 2006; 26:1557-1562.
6. Rieke JW, Hafermann MD, Johnson JT, LeVeque FG, Iwamoto R, Steiger BW, et al. Oral pilocarpine for radiation-induced xerostomia: integrated efficacy and safety results from two prospective randomized clinical trials. Int J Radiat Oncol Biol Phys 1995; 31:661-669.
7. Ferguson MM. Pilocarpine and other cholinergic drugs in the management of salivary gland dysfunction. Oral Surg Oral Med Oral Pathol 1993; 75:186-191.
8. Weaver ML, Tanzer JM, Kramer PA. Salivary flow induction by buccal permucosal pilocarpine in anesthetized beagle dogs. J Dent Res 1992; 71:1762-1767.
9. Tanzer JM, Kramer PA, Schulman P, Willard AK. A pharmacokinetic and pharmacodynamic study of intravenous pilocarpine in humans. J Dent Res 1995; 74:1845-1849.
10. Ellis PP, Littlejohn K, Deitrich RA. Enzymatic hydrolysis of pilocarpine. Investig Ophthalmol 1972; 11:747-751.
11. Aromdee C, Fawcett JP, Ferguson MM, Ledger R. Serum pilocarpine esterase activity and response to oral pilocarpine. Biochem Mol Med 1996; 59:57-61.
12. Endo T, Ban M, Hirata K, Yamamoto A, Hara Y, Momose Y. Involvement of CYP2A6 in the formation of a novel metabolite, 3-hydroxypilocarpine, from pilocarpine in human liver microsomes. Drug Metab Dispos 2007; 35:476-483.
13. Nunoya K, Yokoi T, Kimura K, Kainuma T, Satoh K, Kinoshita M, et al. A new CYP2A6 gene deletion responsible for the in vivo polymorphic metabolism of ( + )-cis-3,5-dimethyl-2-(3-pyridyl) thiazolidin-4-one hydrochloride in humans. J Pharmacol Exp Ther 1999; 289:437-442.
14. Yoshida R, Nakajima M, Watanabe Y, Kwon J-T, Yokoi T. Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism. Br J Clin Pharmacol 2002; 54:511-517.
15. Yoshida R, Nakajima M, Nishimura K, Tokudome S, Kwon J-T, Yokoi T. Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro. Clin Pharmacol Ther 2003; 74:69-76.
16. Nakajima M, Fukami T, Yamanaka H, Higashi E, Sakai H, Yoshida R, et al. Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin Pharmacol Ther 2006; 80:282-297.
17. Lavallee WF, Rosenkrantz H. Evidence for pilocarpine transformation by serum. Biochem Pharmacol 1965; 15:206-210.
18. Van de Merbel NC, Tinke AP, Oosterhuis B, Jonkman JHG, Bohle JF. Determination of pilocarpine, isopilocarpine, pilocarpic acid and isopilocarpic acid in human plasma and urine by high-performance liquid chromatography with tandem mass spectrometric detection. J. Chromatogr Biomed Appl 1998; 708:103-112.
19. Fukami T, Nakajima M, Sakai H, McLeod HL, Yokoi T. CYP2A7 polymorphic alleles confound the genotyping of CYP2A6*4A allele. Pharmacogenomics J 2006; 6:401-412.
20. St. Peter JV, Lambrecht LJ, Gunderson BW, Andersen SA, Gallagher SC, Swan SK. Pharmacokinetics of pilocarpine in subjects with varying degrees of renal function. J Clin Pharmacol 2000; 40:1470-1475.
21. Garg DC, Lasseter KC, Shrotriya RC, Shamblen EC, Shamblen S, Hoff JV, et al. Pharmacokinetic profile of pilocarpine hydrochloride in subjects with impaired hepatic function (abstract P-III-48). Clin Pharmacol Ther 1996; 59:200.
22. Oscarson M, McLellan RA, Gullstén H, Agúndez JAG, Benítez J, Rautio A, et al. Identification and characterization of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism. FEBS Lett 1999; 460:321-327.
23. Nakajima M, Yamagishi S, Yamamoto H, Yamamoto T, Kuroiwa Y, Yokoi T. Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans. Clin Pharmacol Ther 2000; 67:57-69.
24. Nakajima M, Kwon J-T, Tanaka N, Zenta T, Yamamoto Y, Yamamoto H, et al. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans. Clin Pharmacol Ther 2001; 69:72-78.
25. Fukami T, Nakajima M, Yoshida R, Tsuchiya Y, Fujiki Y, Katoh M, et al. A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo. Clin Pharmacol Ther 2004; 76:519-527.
26. Fukami T, Nakajima M, Higashi E, Yamanaka H, Sakai H, McLeod HL, et al. Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity. Drug Metab Dispos 2005; 33:1202-1210.
27. Peamkrasatam S, Sriwatanakul K, Kiyotani K, Fujieda M, Yamazaki H, Kamataki T, et al. In vivo evaluation of coumarin and nicotine as probe drugs to predict the metabolic capacity of CYP2A6 due to genetic polymorphism in Thais. Drug Metab Pharmacokinet 2006; 21:475-484.
28. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270:414-423.
29. Shimada T, Yamazaki H, Guengerich FP. Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations. Xenobiotica 1996; 26:395-403.
30. Wasnich R, Gallagher S, Stanek S, MacDonald JR, Balan G, Omori Y, et al. Salivary flow rates and pharmacokinetics in healthy Japanese and Caucasian volunteers administered oral pilocarpine: a comparative study. Clin Drug Invest 2003; 23:411-417.